Vuist WM - Search Results

1

Two distinct mechanisms of antitumor activity mediated by the combination of interleukin 2 and monoclonal antibodies.

Vuist WM, van Buitenen F, Hekman A, Melief CJ. Vuist WM, et al. Cancer Res. 1990 Sep 15;50(18):5767-72. Cancer Res. 1990. PMID: 1697500

2

Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody.

Hekman A, Honselaar A, Vuist WM, Sein JJ, Rodenhuis S, ten Bokkel Huinink WW, Somers R, Rümke P, Melief CJ. Hekman A, et al. Among authors: vuist wm. Cancer Immunol Immunother. 1991;32(6):364-72. doi: 10.1007/BF01741331. Cancer Immunol Immunother. 1991. PMID: 1706642 Free PMC article. Clinical Trial.

3

Potentiation by interleukin 2 of Burkitt's lymphoma therapy with anti-pan B (anti-CD19) monoclonal antibodies in a mouse xenotransplantation model.

Vuist WM, v Buitenen F, de Rie MA, Hekman A, Rümke P, Melief CJ. Vuist WM, et al. Cancer Res. 1989 Jul 15;49(14):3783-8. Cancer Res. 1989. PMID: 2472198

4

Enhancement of the antibody-dependent cellular cytotoxicity of human peripheral blood lymphocytes with interleukin-2 and interferon alpha.

Vuist WM, Visseren MJ, Otsen M, Bos K, Vyth-Dreese FA, Figdor CG, Melief CJ, Hekman A. Vuist WM, et al. Cancer Immunol Immunother. 1993;36(3):163-70. doi: 10.1007/BF01741087. Cancer Immunol Immunother. 1993. PMID: 8439976 Free PMC article.

5

In vitro investigation of immunoglobulin treatment mechanisms in autoimmune diseases.

Brand A, Vuist WM, Van Schaik IN, Vermeulen M. Brand A, et al. Among authors: vuist wm. Clin Exp Rheumatol. 1996 May-Jun;14 Suppl 15:S27-30. Clin Exp Rheumatol. 1996. PMID: 8828944 Review.

6

Specific tumoricidal activity of cytotoxic macrophages and cytotoxic lymphocytes.

Dullens HF, Schakenraad S, Oostdijk A, Vuist W, Van der Maas M, Den Otter W. Dullens HF, et al. Cancer Immunol Immunother. 1986;22(2):100-6. doi: 10.1007/BF00199122. Cancer Immunol Immunother. 1986. PMID: 3487380 Free PMC article.

7

The role of host lymphocytes and host macrophages in antitumor reactions after injection of sensitized lymphocytes and tumor target cells into naive mice.

Dullens HF, Vuist W, Van der Maas M, Den Otter W. Dullens HF, et al. Cancer Immunol Immunother. 1986;23(2):113-8. doi: 10.1007/BF00199816. Cancer Immunol Immunother. 1986. PMID: 3536093 Free PMC article.

8

The growth arresting effect of human immunoglobulin for intravenous use is mediated by antibodies recognizing membrane glycolipids.

Vuist WM, Van Schaik IN, Van Lint M, Brand A. Vuist WM, et al. J Clin Immunol. 1997 Jul;17(4):301-10. doi: 10.1023/a:1027326731945. J Clin Immunol. 1997. PMID: 9258769

9

Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of bcl-2 protein.

Vuist WM, Levy R, Maloney DG. Vuist WM, et al. Blood. 1994 Feb 15;83(4):899-906. Blood. 1994. PMID: 7509210 Free article.

10

alpha(2A)-adrenergic receptor stimulation potentiates calcium release in platelets by modulating cAMP levels.

Keularts IM, van Gorp RM, Feijge MA, Vuist WM, Heemskerk JW. Keularts IM, et al. Among authors: vuist wm. J Biol Chem. 2000 Jan 21;275(3):1763-72. doi: 10.1074/jbc.275.3.1763. J Biol Chem. 2000. PMID: 10636873 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

16 results

Search Page

Filters